Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), today announces it will advance its second asset, a fully human anti-IL-6 receptor (“IL-6R”) monoclonal antibody, TZLS-501.
Explore how machine learning is revolutionising interstitial lung disease management, enhancing early diagnosis, treatment, ...
Greek yogurt supplementation post-training significantly reduces inflammation markers in young males, offering insights into ...
Bernstein 2nd Annual Global Healthcare Conference September 23, 2025 1:58 PM EDTCompany ParticipantsMatthew Gline - ...
The protein on human cells that tick-borne encephalitis virus (TBEV) uses for infection has now been identified—a major step toward understanding how TBEV causes neurological disease and for ...
Among adults with obesity who lost weight after following a low-calorie diet, weight-loss maintenance with exercise was ...
AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application for Enhertu plus pertuzumab has been accepted for Priority Review b ...
In view of persistent fever and cough, and the new onset of an accentuated confluent maculopapular rash, the patient was ...
Clinical Trials Arena on MSN
Imunon’s IL-12 gene therapy changes “cold” tumour microenvironment to “hot”
Translational results bolster confidence as Phase III trial for IMNN-001 in advance epithelial ovarian cancer gets underway.
India - Grant Romiplostim Lyophilized Formulations Patent With Amendments: Madras High Court Directs. Legal News and Analysis ...
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have rapidly emerged as highly effective pharmacological tools for ...
NEWARK, CALIFORNIA / ACCESS Newswire / September 15, 2025 / Protagonist Therapeutics, Inc. (“Protagonist” or the “Company”) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback